Login to Your Account

Scioderm initiates phase III trial of Zorblisa, targets sea change to treat rare disorder

By Marie Powers
Staff Writer

Wednesday, March 18, 2015

Just three years out of the gate, privately held Scioderm Inc. is starting a phase III registration trial of lead compound Zorblisa (SD-101), its topical therapy to treat blisters and lesions resulting from the rare genetic connective tissue disorder epidermolysis bullosa (EB).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription